MetaCap

Anavex Life Sciences (AVXL) vs OKYO Pharma (OKYO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OKYO Pharma (OKYO) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 49.5% versus a loss of 81.9%. OKYO Pharma is the larger company by market cap ($56.2 million vs $54.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVXL-81.86%OKYO-49.53%
+70%-10%-89%
Nov 21, 20251 yearNov 20, 2026
AVXL-93.85%OKYO-64.33%
+57%-22%-101%
May 16, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVXL versus OKYO key metrics
MetricAVXLOKYO
Share price$0.5915$1.07
Market cap$54.83M$56.15M
1-day change-11.39%-7.76%
YTD return-83.38%-48.31%
1-year return-81.86%-49.53%
5-year return-96.96%—
EPS (TTM)$-0.14$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-46.38M$-4.71M
52-week high$5.36$3.20
52-week low$0.59$1.00
Distance from 52-week high-88.96%-66.56%
Analyst consensusnonestrong_buy
Avg. price target upside—+678.50%
Average volume1.15M143.41K
Shares outstanding92.70M52.48M
Employees345
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OKYO has outperformed AVXL by 32.3 percentage points over the past year.

About Anavex Life Sciences

AVXL stock →

Anavex Life Sciences Corp. operates as a biopharmaceutical company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

About OKYO Pharma

OKYO stock →

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

AVXL vs OKYO FAQ

Which is bigger, Anavex Life Sciences or OKYO Pharma?

OKYO Pharma (OKYO) is larger, with a market capitalization of $56.15M compared with $54.83M for Anavex Life Sciences (AVXL).

Which stock has performed better over the past year, AVXL or OKYO?

OKYO returned -49.53% over the past 12 months, compared with -81.86% for AVXL (price return, excluding dividends). Past performance does not predict future results.

Are Anavex Life Sciences and OKYO Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons